Iterum Therapeutics Valuation
| ITRM Stock | USD 0.20 0.01 4.76% |
Iterum Therapeutics seems to be undervalued based on Macroaxis valuation methodology. Our model calculates the value of Iterum Therapeutics PLC from evaluating the firm fundamentals such as Return On Asset of -0.53, return on equity of -5.56, and Shares Outstanding of 53.29 M as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Iterum Therapeutics' valuation include:
Price Book 6.0287 | Enterprise Value | Enterprise Value Ebitda 0.5453 | Price Sales 28.9688 | Enterprise Value Revenue 105.2207 |
Undervalued
Today
Please note that Iterum Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of Iterum Therapeutics PLC is based on 3 months time horizon. Increasing Iterum Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Iterum stock is determined by what a typical buyer is willing to pay for full or partial control of Iterum Therapeutics PLC. Since Iterum Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Iterum Stock. However, Iterum Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.2 | Real 1.53 | Target 5.5 | Hype 0.23 | Naive 0.2 |
The intrinsic value of Iterum Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Iterum Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Iterum Therapeutics PLC helps investors to forecast how Iterum stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Iterum Therapeutics more accurately as focusing exclusively on Iterum Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Iterum Therapeutics' intrinsic value based on its ongoing forecasts of Iterum Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Iterum Therapeutics' closest peers.
Iterum Therapeutics Cash |
|
Iterum Therapeutics Total Value Analysis
Iterum Therapeutics PLC is currently projected to have valuation of 49.44 M with market capitalization of 11.3 M, debt of 45.53 M, and cash on hands of 68.91 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Iterum Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
49.44 M | 11.3 M | 45.53 M | 68.91 M |
Iterum Therapeutics Asset Utilization
One of the ways to look at asset utilization of Iterum is to check how much profit was generated for every dollar of assets it reports. Iterum Therapeutics retains a negative application of resources of -0.53 (percent), losing $0.005328 for each dollar of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of Iterum Therapeutics PLC shows how discouraging it operates for each dollar spent on its resources.Iterum Therapeutics Profitability Analysis
Based on Iterum Therapeutics' profitability indicators, Iterum Therapeutics PLC may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in March. Profitability indicators assess Iterum Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2016-12-31 | Previous Quarter -6.5 M | Current Value -9 M | Quarterly Volatility 17 M |
For Iterum Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Iterum Therapeutics PLC to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Iterum Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Iterum Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Iterum Therapeutics over time as well as its relative position and ranking within its peers.
Iterum Therapeutics Earnings per Share Projection vs Actual
By analyzing Iterum Therapeutics' earnings estimates, investors can diagnose different trends across Iterum Therapeutics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Iterum Therapeutics PLC is based on EPS before non-recurring items and includes expenses related to employee stock options.Iterum Therapeutics Ownership Allocation
Iterum Therapeutics PLC has a total of 53.29 Million outstanding shares. Roughly 93.33 (percent) of Iterum Therapeutics outstanding shares are held by general public with 0.78 % owned by insiders and only 5.89 pct. by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Iterum Therapeutics Profitability Analysis
Net Loss for the year was (24.77 M) with profit before overhead, payroll, taxes, and interest of 116 K.About Iterum Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Iterum Therapeutics PLC. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Iterum Therapeutics PLC based exclusively on its fundamental and basic technical indicators. By analyzing Iterum Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Iterum Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Iterum Therapeutics. We calculate exposure to Iterum Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Iterum Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -228.6 K | -240 K | |
| Pretax Profit Margin | -3.2 K | -3 K | |
| Operating Profit Margin | -3.2 K | -3 K | |
| Net Loss | -3.2 K | -3 K |
Iterum Therapeutics Current Valuation Indicators
Iterum Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Iterum Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Iterum Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Iterum Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Iterum Therapeutics' worth.When determining whether Iterum Therapeutics PLC is a strong investment it is important to analyze Iterum Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Iterum Therapeutics' future performance. For an informed investment choice regarding Iterum Stock, refer to the following important reports: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Will Pharmaceuticals sector continue expanding? Could Iterum diversify its offerings? Factors like these will boost the valuation of Iterum Therapeutics. Market participants price Iterum higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Iterum Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.72) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
Understanding Iterum Therapeutics PLC requires distinguishing between market price and book value, where the latter reflects Iterum's accounting equity. The concept of intrinsic value - what Iterum Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Iterum Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Iterum Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.